Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127956 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Dermira.
- Completed
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
- 20
- Study locations
NCT03127956: Completed Phase 3 study of Acne Vulgaris, sponsored by Dermira.
NCT03127956 is a Phase 3 study of Acne Vulgaris that has completed, run by Dermira. The registered enrollment target is 748 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (183% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03127956, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Dermira.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
Primary Outcome
Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions
Conditions Studied
Interventions
- DRUG Olumacostat Glasaretil Gel, 5.0%
Study Locations (20)
California
- Anaheim Clinical Trials - Anaheim
- Center for Dermatology Clinical Research, Inc. - Fremont
- Advanced Skincare Surgery & MedCenter - Fullerton
- Dermatology Research Associates - Los Angeles
- Northern California Research - Sacramento
- Rady Children's Hospital UCSD Pediatric and Adolescent Derm - San Diego
- TCR Medical Corporation - San Diego
- University Clinical Trials Inc. - San Diego
- Radiant Research, Inc. - Santa Rosa
Florida
- Center for Clincial and Cosmetic Research - Aventura
- Florida Academic Centers Research & Education - Coral Gables
- Aby's New Generation Research Inc. - Hialeah
Arizona
- Advanced Research Associates - Glendale
- Alliance Dermatology & MOHS Center - Phoenix
Arkansas
- Dermatology Trial Associates - Bryant
- Northwest Arkansas Clinical Trials Center - Rogers
Colorado
- Alpine Clinical Research Center - Boulder
- Horizons Clinical Research Center, LLC - Denver
Alabama
- Avant Research Associates, LLC - Guntersville
Connecticut
- Dermatology Physicians of CT - Shelton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 3 |
What the finished NCT03127956 record still lists
NCT03127956 is an interventional study that assigns participants to a tested intervention. The registered 748 participants enrollment target is mid-sized for trials with a published cap, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (183% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Olumacostat Glasaretil Gel, 5.0% is the first listed.
NCT03127956 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03127956 about?
NCT03127956 is a clinical study titled "A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris". The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
What is the current status of trial NCT03127956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2017-03-21. Estimated completion is 2018-04-27.
What conditions does trial NCT03127956 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03127956?
The interventions under investigation include: Olumacostat Glasaretil Gel, 5.0% (DRUG).
Who is sponsoring clinical trial NCT03127956?
This trial is sponsored by Dermira, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03127956 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03127956's enrollment target sits among peer trials
748 7th of 67 higher than 61 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI